DK1262546T3 - Hidtil ukendte scavenger-receptorer - Google Patents

Hidtil ukendte scavenger-receptorer

Info

Publication number
DK1262546T3
DK1262546T3 DK01902805T DK01902805T DK1262546T3 DK 1262546 T3 DK1262546 T3 DK 1262546T3 DK 01902805 T DK01902805 T DK 01902805T DK 01902805 T DK01902805 T DK 01902805T DK 1262546 T3 DK1262546 T3 DK 1262546T3
Authority
DK
Denmark
Prior art keywords
same
scavenger receptors
proteins
lipoproteinemia
elucidation
Prior art date
Application number
DK01902805T
Other languages
English (en)
Inventor
Nobutaka Wakamiya
Original Assignee
Fuso Pharmaceutical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuso Pharmaceutical Ind filed Critical Fuso Pharmaceutical Ind
Application granted granted Critical
Publication of DK1262546T3 publication Critical patent/DK1262546T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
DK01902805T 2000-02-14 2001-02-08 Hidtil ukendte scavenger-receptorer DK1262546T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000035155 2000-02-14
JP2000309068 2000-10-10
PCT/JP2001/000874 WO2001059107A1 (en) 2000-02-14 2001-02-08 Novel scavenger receptors

Publications (1)

Publication Number Publication Date
DK1262546T3 true DK1262546T3 (da) 2010-01-04

Family

ID=26585296

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01902805T DK1262546T3 (da) 2000-02-14 2001-02-08 Hidtil ukendte scavenger-receptorer

Country Status (12)

Country Link
US (5) US7189809B2 (da)
EP (1) EP1262546B1 (da)
JP (1) JP4685315B2 (da)
KR (1) KR100514521B1 (da)
CN (1) CN100485035C (da)
AT (1) ATE441665T1 (da)
AU (2) AU3059401A (da)
CA (1) CA2399865C (da)
DE (1) DE60139765D1 (da)
DK (1) DK1262546T3 (da)
ES (1) ES2331107T3 (da)
WO (1) WO2001059107A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1262546B1 (en) * 2000-02-14 2009-09-02 Fuso Pharmaceutical Industries Ltd. Novel scavenger receptors
US20080268478A1 (en) * 2005-03-01 2008-10-30 Cedars-Sinai Medical Center Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation
JPWO2007139120A1 (ja) * 2006-05-30 2009-10-08 国立大学法人大阪大学 アミロイドβクリアランス促進剤
EP2559760B1 (en) 2010-03-04 2015-10-21 Fuso Pharmaceutical Industries, Ltd. Collectin fragment for the treatment of vascular disease
CN110226567A (zh) * 2019-06-19 2019-09-13 北京林业大学 一种利用黑腹果蝇评价邻苯二甲酸酯类增塑剂的生殖毒性的方法
CN113430985A (zh) * 2021-07-02 2021-09-24 广西壮族自治区自然资源生态修复中心 乡村河道多层式生态保护修复方法
EP4685487A1 (en) * 2023-03-23 2026-01-28 Sekisui Medical Co., Ltd. Method for measuring pulmonary surfactant protein d, measurement kit, monoclonal antibody, and cell

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK570485D0 (da) 1985-12-10 1985-12-10 Novo Industri As Humant conglutinin
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
WO1989001519A1 (en) 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
JPH079124B2 (ja) 1988-07-28 1995-02-01 株式会社城南製作所 駆動装置
JP2504581B2 (ja) 1989-09-08 1996-06-05 富士通株式会社 ディジタル信号伝送方式
US5866373A (en) * 1995-04-21 1999-02-02 Human Genome Sciences, Inc. Polynucleotide encoding a human chemotactic protein
CA2229775C (en) 1995-08-17 2003-07-22 Fuso Pharmaceutical Industries, Ltd. Recombinant conglutinin and producing method thereof
JPH09238683A (ja) 1996-03-12 1997-09-16 Eijiin Kenkyusho:Kk ウェルナー症候群の原因遺伝子の存在する領域にある新規ｗｓ−３遺伝子及びその遺伝子がコードするタンパク質
JP3233057B2 (ja) 1997-02-27 2001-11-26 日本鋼管株式会社 溶融めっき鋼板のスパングルサイズの測定方法
AU7807298A (en) * 1997-06-04 1998-12-21 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
JP3878737B2 (ja) 1998-01-23 2007-02-07 扶桑薬品工業株式会社 新規コレクチン
CN1320164A (zh) * 1998-08-24 2001-10-31 扶桑药品工业株式会社 新的聚集蛋白
EP1177296A2 (en) 1999-05-11 2002-02-06 Incyte Genomics, Inc. Extracellular matrix and adhesion-associated proteins
EP1262546B1 (en) * 2000-02-14 2009-09-02 Fuso Pharmaceutical Industries Ltd. Novel scavenger receptors
DK1283214T3 (da) 2000-04-21 2007-06-11 Fuso Pharmaceutical Ind Hidtil ukendte kollektiner

Also Published As

Publication number Publication date
US20100113749A1 (en) 2010-05-06
CA2399865C (en) 2011-10-25
CN1646689A (zh) 2005-07-27
CN100485035C (zh) 2009-05-06
KR100514521B1 (ko) 2005-09-14
US8410253B2 (en) 2013-04-02
US20070224649A1 (en) 2007-09-27
US7612174B2 (en) 2009-11-03
DE60139765D1 (de) 2009-10-15
KR20020089351A (ko) 2002-11-29
AU2001230594B2 (en) 2004-11-11
US8084578B2 (en) 2011-12-27
CA2399865A1 (en) 2001-08-16
EP1262546A4 (en) 2004-07-14
WO2001059107A1 (en) 2001-08-16
US20100113750A1 (en) 2010-05-06
US20030108904A1 (en) 2003-06-12
EP1262546A1 (en) 2002-12-04
JP4685315B2 (ja) 2011-05-18
ATE441665T1 (de) 2009-09-15
AU3059401A (en) 2001-08-20
US7189809B2 (en) 2007-03-13
EP1262546B1 (en) 2009-09-02
US7612175B2 (en) 2009-11-03
ES2331107T3 (es) 2009-12-22
US20070231859A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
Michels et al. Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis
DE602004009705D1 (de) Methoden der Verhinderung und Behandlung der Alzheimer'schen Krankheit
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
AU2003270643A1 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
CY1116776T1 (el) Αντισωματα ειδικα για τα διαλυτα πρωτοϊνιδια των πεπτιδιων β-αμυλοειδους και χρησεις αυτων
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
PL392964A1 (pl) Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
DE60142614D1 (de) Inität
BRPI0410684A (pt) uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
AU2002223640A1 (en) Fusion proteins as immunization treatments of alzheimer's disease
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
DK1441764T3 (da) Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom
ATE441665T1 (de) Scavenger-rezeptoren
Laustsen et al. In vivo neutralization of myotoxin II, a phospholipase A2 homologue from Bothrops asper venom, using peptides discovered via phage display technology
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
WO2002057796A3 (en) Compounds for treating pathologies associated with molecular crystallization
ATE393170T1 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
ATE401402T1 (de) Mit syndekan interagierende proteine und deren verwendung
WO2001090187A3 (en) G-protein coupled olfactory receptors
Lozano et al. Redefining an epitope of a malaria vaccine candidate, with antibodies against the N-terminal MSA-2 antigen of Plasmodium harboring non-natural peptide bonds
DE69630761D1 (de) Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten
AU2002350406A1 (en) Identification of ses-3 (spr-5) in c. elegans and the uses of the same